The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation
Open accessAbstract
Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal adenocarcinoma. The factors that result in IBD-associated carcinogenesis are not understood. We hypothesized that altered expression of intestinal epithelial tight junction proteins might contribute to neoplastic progression. Semiquantitative immunohistochemical staining of human biopsies was used to assess expression of the tight junction proteins claudin-1, claudin-2, claudin-4, and occludin in IBD, IBD-associated dysplasia, acute, self-limited colitis (ASLC), and sporadic adenomas. Claudin-1 and claudin-2 expression was elevated in active IBD, adenomas, and IBD-associated dysplasia, but not ASLC. In contrast, claudin-4 expression was elevated in both active IBD and ASLC. Occludin expression was similar to control in all cases. Importantly, in IBD, claudin-1 and claudin-2 expression correlated positively with inflammatory activity. To investigate mechanisms underlying altered claudin expression, β-catenin activation was assessed as nuclear localization. Like claudin-1 and claudin-2, β-catenin was markedly activated in IBD, sporadic dysplasia, and IBD-associated dysplasia, but was only slightly activated in ASLC. Taken together, these data suggest that β-catenin transcriptional activity is elevated in chronic injury and that this may contribute to increased claudin-1 and claudin-2 expression. We speculate that increased claudin-1 and claudin-2 expression may be involved at early stages of transformation in IBD-associated neoplasia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itzkowitz, S. H., & Yio, X. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2004 · Cited by 1,274
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Rutter, M., Saunders, B., Wilkinson, K., Rumbles, S., Schofield, G., Kamm, M., Williams, C., Price, A., Talbot, I., & Forbes, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.010 · Cited by 1,255
HELLER, F., FLORIAN, P., BOJARSKI, C., RICHTER, J., CHRIST, M., HILLENBRAND, B., MANKERTZ, J., GITTER, A., BURGEL, N., & FROMM, M. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.002 · Cited by 1,230
Zeissig, S., Bürgel, N., Günzel, D., Richter, J., Mankertz, J., Wahnschaffe, U., Kroesen, A. J., Zeitz, M., Fromm, M., & Schulzke, J.-D. (2007) · Gut · doi:10.1136/gut.2006.094375 · Cited by 1,223
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Signalling to and from tight junctions
Matter, K., & Balda, M. S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1055 · Cited by 884
Fuss, I. J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., Yang, Z., Exley, M., Kitani, A., Blumberg, R. S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19836 · Cited by 797
Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., & Turner, J. R. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62264-x · Cited by 696
Self-citationSchmitz*, H., Barmeyer*, C., Fromm‡, M., Runkel§, N., Foss∥, H.-D., Bentzel¶, C. J., Riecken*, E.-O., & Schulzke*, J.-D. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70126-5 · Cited by 607
Claudin Proteins in Human Cancer: Promising New Targets for Diagnosis and Therapy
Morin, P. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2782 · Cited by 574
Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer
Dhawan, P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24543 · Cited by 566
Molecular Basis of Epithelial Barrier Regulation
Turner, J. R. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060681 · Cited by 541
Self-citationA porous defense: the leaky epithelial barrier in intestinal disease
Clayburgh, D. R., Shen, L., & Turner, J. R. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700050 · Cited by 498
Self-citationThe claudin gene family: expression in normal and neoplastic tissues
Hewitt, K. J., Agarwal, R., & Morin, P. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-186 · Cited by 497
Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells
Prasad, S., Mingrino, R., Kaukinen, K., Hayes, K. L., Powell, R. M., MacDonald, T. T., & Collins, J. E. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700316 · Cited by 490
MACDONALD, T. T., HUTCHINGS, P., CHOY, M.-Y., MURCH, S., & COOKE, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb03334.x · Cited by 478
Clayburgh, D. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24970 · Cited by 426
The Risk of Cancer in Patients with Crohn's Disease
von Roon, A. C., Reese, G., Teare, J., Constantinides, V., Darzi, A. W., & Tekkis, P. P. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0848-z · Cited by 319
Wang, F., Schwarz, B. T., Graham, W. V., Wang, Y., Su, L., Clayburgh, D. R., Abraham, C., & Turner, J. R. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.022 · Cited by 310
Self-citationSurawicz, C. M., & Belic, L. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90595-x · Cited by 306
Blair, S. A., Kane, S. V., Clayburgh, D. R., & Turner, J. R. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700373 · Cited by 299
Self-citationMiwa, N., Furuse, M., Tsukita, S., Niikawa, N., Nakamura, Y., & Furukawa, Y. (2001) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504001108747477 · Cited by 298
Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer.
Michl, P., Barth, C., Buchholz, M., Lerch, M. M., Rolke, M., Holzmann, K., Menke, A., Fensterer, H., Giehl, K., Löhr, M. J., et al. (2003) · PubMed · Cited by 295
Expression from the human occludin promoter is affected by tumor necrosis factor α and interferon γ
Mankertz, J., Tavalali, S., Schmitz, H., Mankertz, A., Riecken, E. O., Fromm, M., & Schulzke, J. D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2085 · Cited by 287
Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study
Resnick, M. B., Konkin, T., Routhier, J., Sabo, E., & Pricolo, V. E. (2005) · Modern Pathology · doi:10.1038/modpathol.3800301 · Cited by 250
Role of claudins in tumorigenesis
SWISSHELM, K., MACEK, R., & KUBBIES, M. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.01.006 · Cited by 232
Surawicz, C. M., Haggitt, R. C., Husseman, M., & McFarland, L. V. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90124-4 · Cited by 228
Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours
Soini, Y. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02127.x · Cited by 200
Claudins: emerging targets for cancer therapy
Kominsky, S. L. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000056 · Cited by 160
Graham, W. V., Wang, F., Clayburgh, D. R., Cheng, J. X., Yoon, B., Wang, Y., Lin, A., & Turner, J. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602164200 · Cited by 148
Self-citationInflammatory bowel disease: is it really just another break in the wall?: Figure 1
Weber, C. R., & Turner, J. R. (2006) · Gut · doi:10.1136/gut.2006.104182 · Cited by 141
Self-citationSelective up-regulation of claudin-1 and claudin-2 in colorectal cancer.
Kinugasa, T., Huo, Q., Higashi, D., Shibaguchi, H., Kuroki, M., Tanaka, T., Futami, K., Yamashita, Y., Hachimine, K., Maekawa, S., et al. (2007) · PubMed · Cited by 126
Colorectal carcinoma and inflammatory bowel disease
Eaden, J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02046.x · Cited by 112
Mankertz, J., Hillenbrand, B., Tavalali, S., Huber, O., Fromm, M., & Schulzke, J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.185 · Cited by 106
Gröne, J., Weber, B., Staub, E., Heinze, M., Klaman, I., Pilarsky, C. P., Hermann, K., Castaños‐Vélez, E., Röpcke, S., Mann, B., et al. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0197-3 · Cited by 93
Shiou, S., Singh, A. B., Krishnan, M., Datta, P. K., Washington, M. K., Beauchamp, R. D., & Dhawan, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1680 · Cited by 83
Colorectal Cancer in Patients with Inflammatory Bowel Disease
Vagefi, P. A., & Longo, W. E. (2005) · Clinical Colorectal Cancer · doi:10.3816/ccc.2005.n.003 · Cited by 70
Cited by
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952
“This may explain the increased claudin-1 expression by intestinal epithelial cells of patients with inflammatory bowel diseas”
BackgroundClaudins and the Modulation of Tight Junction Permeability
Günzel, D., & Yu, A. S. L. (2013) · Physiological Reviews · doi:10.1152/physrev.00019.2012 · Cited by 1,456
The intestinal epithelial barrier: a therapeutic target?
Odenwald, M. A., & Turner, J. R. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.169 · Cited by 1,288
Self-citationRoda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., Kaser, A., Peyrin-Biroulet, L., & Danese, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0156-2 · Cited by 1,023
Tight Junction Pore and Leak Pathways: A Dynamic Duo
Shen, L., Weber, C. R., Raleigh, D. R., Yu, D., & Turner, J. R. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142150 · Cited by 872
Self-citation
Metadata
- Authors
- Weber, C. R., Nalle, S. C., Tretiakova, M., Rubin, D. T., & Turner, J. R.
- Venue
- Laboratory Investigation
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 88
- Issue
- 10
- Pages
- 1110-1120
- ISSN
- 0023-6837 (ISSN-L)
- OpenAlex
- W2026700628
- Cited by
- 370
- References
- 37
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.